Adagrasib is an irreversible KRAS G12C inhibitor that is designed to have a 23-hour half-life, dose-dependent pharmacokinetics, and central nervous system penetration. The pooled analysis of Phase I/II (KRYSTAL-1) trial that was presented during the AACR 2024 conference demonstrated that, as of the data cutoff date of June 30, 2023, and a median follow-up of 11.9 months, the ORR achieved by the combination as per blinded independent central review (BICR) was 34.0% and the disease control rate was 85.1%. Moreover, the median duration of response (DOR) was 5.8 months. Further findings showed that the median PFS was 6.9 months and the 6-month PFS rate was 57.7%. The medi...
